YS Biopharma (YSB) Competitors

YSB vs. KURA, ARDX, DAWN, AVDL, XNCR, SYRE, GYRE, PRAX, COLL, and NRIX

Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include Kura Oncology (KURA), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), Avadel Pharmaceuticals (AVDL), Xencor (XNCR), Spyre Therapeutics (SYRE), Gyre Therapeutics (GYRE), Praxis Precision Medicines (PRAX), Collegium Pharmaceutical (COLL), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

YS Biopharma vs.

Kura Oncology (NASDAQ:KURA) and YS Biopharma (NASDAQ:YSB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.

: In the previous week, Kura Oncology had 9 more articles in the media than YS Biopharma. MarketBeat recorded 9 mentions for Kura Oncology and 0 mentions for YS Biopharma. Kura Oncology's average media sentiment score of 0.55 beat YS Biopharma's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.
Company Overall Sentiment
Kura Oncology Positive
YS Biopharma Neutral
: 52.6% of YS Biopharma shares are held by institutional investors. 5.5% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Kura Oncology currently has a consensus price target of $29.20, indicating a potential upside of 62.13%. YS Biopharma has a consensus price target of $5.25, indicating a potential upside of 0.00%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than YS Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
0 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.83
YS Biopharma
0 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Kura Oncology received 410 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 69.08% of users gave Kura Oncology an outperform vote.
Company Underperform Outperform
Kura Oncology Outperform Votes
411
69.08%
Underperform Votes
184
30.92%
YS Biopharma Outperform Votes
1
100.00%
Underperform Votes
No Votes
: YS Biopharma's return on equity of 0.00% beat Kura Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Kura Oncology N/A -40.43% -36.50%
YS Biopharma N/A N/A N/A
: YS Biopharma has higher revenue and earnings than Kura Oncology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology N/A N/A -$152.63M -$2.17 -8.29
YS Biopharma $560.76M 0.00 -$21.17M N/A N/A
: Kura Oncology has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Company	Overall Sentiment
Kura Oncology	Positive
YS Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
YS Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Underperform	Outperform
Kura Oncology	Outperform Votes 411 69.08%	Underperform Votes 184 30.92%
YS Biopharma	Outperform Votes 1 100.00%	Underperform Votes No Votes

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	N/A	-40.43%	-36.50%
YS Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	N/A	N/A	-$152.63M	-$2.17	-8.29
YS Biopharma	$560.76M	0.00	-$21.17M	N/A	N/A

Summary

Kura Oncology and YS Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

Ad Paradigm Press

[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Get YS Biopharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YSB vs. The Competition

Export to Excel

Metric	YS Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$344.32M	$6.35B	$5.43B	$8.47B
Dividend Yield	N/A	9.06%	4.63%	4.11%
P/E Ratio	N/A	20.58	141.84	20.02
Price / Sales	N/A	256.68	1,164.90	72.85
Price / Cash	N/A	47.28	38.25	33.56
Price / Book	N/A	5.78	4.87	4.66
Net Income	-$21.17M	$135.19M	$119.46M	$226.78M

YS Biopharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YSB YS Biopharma	N/A	N/A	$5.25 +∞	N/A	$344.32M	$560.76M	0.00	773
KURA Kura Oncology	4.1134 of 5 stars	$17.99 -1.5%	$29.20 +62.3%	+107.5%	$1.37B	N/A	-8.07	142	Analyst Downgrade Short Interest ↓
ARDX Ardelyx	4.307 of 5 stars	$5.79 -1.0%	$11.67 +101.5%	+69.0%	$1.35B	$210.00M	-21.44	267	Short Interest ↓
DAWN Day One Biopharmaceuticals	2.7387 of 5 stars	$15.24 +1.5%	$35.71 +134.3%	+43.9%	$1.33B	$8.19M	-7.82	60	Positive News
AVDL Avadel Pharmaceuticals	3.0154 of 5 stars	$13.80 +4.2%	$24.57 +78.1%	+20.9%	$1.33B	$95.15M	-11.79	154	Short Interest ↓ News Coverage Positive News
XNCR Xencor	3.8707 of 5 stars	$21.30 -1.0%	$34.78 +63.3%	+11.0%	$1.31B	$133.62M	-7.37	280	Gap Down
SYRE Spyre Therapeutics	2.0983 of 5 stars	$32.29 -0.2%	$43.43 +34.5%	N/A	$1.30B	$890,000.00	-2.09	100
GYRE Gyre Therapeutics	0.2638 of 5 stars	$13.81 -1.3%	N/A	N/A	$1.29B	$113.45M	0.00	40	Upcoming Earnings
PRAX Praxis Precision Medicines	3.5012 of 5 stars	$74.28 +0.3%	$143.44 +93.1%	+271.4%	$1.27B	$1.77M	-7.25	110	Positive News
COLL Collegium Pharmaceutical	3.0855 of 5 stars	$38.77 -1.4%	$42.60 +9.9%	+77.3%	$1.27B	$576.65M	15.03	210	Analyst Upgrade Short Interest ↓
NRIX Nurix Therapeutics	1.9071 of 5 stars	$25.72 -0.3%	$28.71 +11.6%	+306.6%	$1.26B	$62.30M	-8.81	300	Earnings Report Analyst Forecast News Coverage